CD274 and non-small cell lung carcinoma: Immunological checkpoint inhibitors targeting PD-1/PD-L1 are benefcial to patients, both in the frst-line and second-line treatment of advanced NSCLC, in the adjuvant treatment of locally-advanced NSCLC, and in the neoadjuvant therapy of early NSCLC, which show an important role in the comprehensive treatment of NSCLC.